Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: A single center experience

被引:24
作者
Zhang, Li [1 ,2 ,3 ]
Zhao, Hui [1 ,2 ,3 ]
Zhu, Xiaofan [1 ,2 ,3 ]
Chen, Yumei [1 ,2 ,3 ]
Zou, Yao [1 ,2 ,3 ]
Chen, Xiaojuan [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Hematol, Dept Pediat, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Inst Hematol, Dept Pediat, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
关键词
acute promyelocytic leukemia; As(2)O(3); ATRA; children;
D O I
10.1002/pbc.21510
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background There are very limited data reported about childhood acute promyelocytic leukemia (APL), especially with arsenic trioxide (As(2)O(3)) treatment. We review the clinical course and treatment outcome of 65 children APL. Procedure. Between January 1999 and December 2005, 65 children (<18 years) with newly diagnosed APL were treated. Results. Three groups of patients were identified according to the different induction regimens. Forty patients were given ATRA alone (group 1, G1), 8 patients were given As(2)O(3) alone (group 2, G2), 15 patients (group 3, G3) were treated with combination of ATRA and As(2)O(3). Two patients received cytosine arabinoside and died at days 2 and 4, respectively. The CR rate of G1 was 95% (38/40). The overall CR rate of G2+G3 was 91.3% (21/23). Toxicity of ATRA and As(2)O(3) were minimal and recoverable during induction. Five children had a hematologic relapse and two developed molecular relapse. Five of them were successfully treated with ATRA alone or combined with As(2)O(3). The 5-year estimate of EFS, DFS and OS between G1 and G2+G3 has no difference. Conclusion. As(2)O(3) is an effective and well tolerable therapy for children with APL and it may be used in those who have dose limiting side effects of ATRA, but also for those with newly diagnosed or relapsed APL.
引用
收藏
页码:210 / 215
页数:6
相关论文
共 18 条
[1]
AIDA (all-trans retinoic acid plus idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot study [J].
Avvisati, G ;
LoCoco, F ;
Diverio, D ;
Falda, M ;
Ferrara, F ;
Lazzarino, M ;
Russo, D ;
Petti, MC ;
Mandelli, F .
BLOOD, 1996, 88 (04) :1390-1398
[2]
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[3]
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy [J].
de Botton, S ;
Coiteux, V ;
Chevret, S ;
Rayon, C ;
Vilmer, E ;
Sanz, M ;
de La Serna, J ;
Philippe, N ;
Baruchel, A ;
Leverger, G ;
Robert, A ;
Miguel, JS ;
Conde, E ;
Sotto, JJ ;
Bordessoule, D ;
Fegueux, N ;
Fey, M ;
Parry, A ;
Chomienne, C ;
Degos, L ;
Fenaux, P .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1404-1412
[4]
THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA [J].
FRANKEL, SR ;
EARDLEY, A ;
LAUWERS, G ;
WEISS, M ;
WARRELL, RP .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (04) :292-296
[5]
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience [J].
George, B ;
Mathews, V ;
Poonkuzhali, B ;
Shaji, RV ;
Srivastava, A ;
Chandy, M .
LEUKEMIA, 2004, 18 (10) :1587-1590
[6]
Acute promyelocytic leukaemia in children [J].
Gregory, J ;
Feusner, J .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2003, 16 (03) :483-494
[7]
Immunophenotype of adult and childhood acute promyelocytic leukaemia:: correlation with morphology, type of PML gene breakpoint and clinical outcome.: A cooperative Italian study on 196 cases [J].
Guglielmi, C ;
Martelli, MP ;
Diverio, D ;
Fenu, S ;
Vegna, ML ;
Cantù-Rajnoldi, A ;
Biondi, A ;
Cocito, MG ;
Del Vecchio, L ;
Tabilio, A ;
Avvisati, G ;
Basso, G ;
Lo Coco, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (04) :1035-1041
[8]
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia [J].
Kell, WJ ;
Burnett, AK ;
Chopra, R ;
Yin, JAL ;
Clark, RE ;
Rohatiner, A ;
Culligan, D ;
Hunter, A ;
Prentice, AG ;
Milligan, DW .
BLOOD, 2003, 102 (13) :4277-4283
[9]
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia [J].
Lo Coco, F ;
Diverio, D ;
Falini, B ;
Biondi, A ;
Nervi, C ;
Pelicci, PG .
BLOOD, 1999, 94 (01) :12-22
[10]
Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children [J].
Mann, G ;
Reinhardt, D ;
Ritter, J ;
Hermann, J ;
Schmitt, K ;
Gadner, H ;
Creutzig, U .
ANNALS OF HEMATOLOGY, 2001, 80 (07) :417-422